<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424707</url>
  </required_header>
  <id_info>
    <org_study_id>DW340-P2</org_study_id>
    <nct_id>NCT03424707</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of DW340 in Patients With Acute Low Back Pain</brief_title>
  <official_title>A Single-Center, Randomized, Double-Blind, Parallel, Pilot Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of DW340 in Patients With Acute Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single-Center, Randomized, Double-Blind, Parallel, Pilot Study to Evaluate the Efficacy and
      Safety of Fixed Dose Combination of Pelubiprofen/Eperisone in Patients with Acute Low Back
      Pain
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2016</start_date>
  <completion_date type="Actual">August 30, 2016</completion_date>
  <primary_completion_date type="Actual">August 30, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>100mm VAS</measure>
    <time_frame>7 days</time_frame>
    <description>The change of 100mm movement pain VAS between basline and end point</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Acute Low Back Pain</condition>
  <arm_group>
    <arm_group_label>combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>single</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW340(pelubiprofen/eperisone)</intervention_name>
    <description>DW340</description>
    <arm_group_label>combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pelubi(pelubiprofen)</intervention_name>
    <description>pelubiprofen</description>
    <arm_group_label>single</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo Oral Tablet</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults over 19 years of age

          2. Patients with a paraxial (muscle spasm) of less than 21 days and acute lower back
             pain. Randomized intervention. Arterial pain 100 mm - visual analogue scale (VAS)

          3. Participation and voluntary agreement

        Exclusion Criteria:

          1. Drugs for Clinical Trial or Similar Drugs and Components with Hypersensitivity or
             Aspirin or Nonsteroidal Anti-inflammatory Drugs

          2. Those accompanying the following diseases (1) patients with severe underlying diseases
             that cause back pain (eg, cancer, spinal infections, cauda equina syndrome, spinal
             stenosis, neuropathy, vertebral compression fracture, posterior hiatal joint syndrome,
             intervertebral disc herniation, fibromyalgia, Spondylolisthesis, imaging confirmed
             degenerative spondylosis, severe arthritis or severe osteoporosis) (2) myositis,
             muscular atrophy, myotonia, myasthenia (3) peptic ulcer or duodenal ulcer (4)
             Gastrointestinal bleeding or bleeding disorder (5) severe heart failure (NYHA class
             III / IV) (6) Uncontrolled hypertension (SBP ≥ 180 mmHg or DBP ≥ 110 mmHg) (7) Liver
             impairment (AST or ALT ≥ 3 × upper normal level of the organ) or renal impairment
             (CLcr &lt;30 mL / min)

          3. Those who have confirmed the following history or surgery / (1) lumbar surgery (2)
             Unstable angina pectoris, myocardial infarction, transient ischemic attack, stroke,
             coronary artery bypass surgery or coronary artery bypass graft within 6 months from
             screening (3) galactose intolerance, Lapp lactase deficiency or glucose-galactose
             malabsorption, (4) malignant tumor within 5 years from the screening point

          4. Drugs that may affect the following efficacy evaluations during clinical trials, or
             those expected to require drug interactions with the clinical trial drug (provided
             there is a separate standard, such as a nonsteroidal anti-inflammatory drug) Follow
             the standard.) (1) Nonsteroidal antiinflammatory drugs: pelubiprofen, aceclofenac,
             diclofenac, ketorolac (from 1 week before randomization until the end of the clinical
             trial, except oxaprozin and oxicam 2 weeks before randomization) (2) Muscle relaxants:
             eperisone, baclofen, cyclobenzaprine, dantrolene, thiocolchicoside, tizanidine (from 1
             week before randomization until the end of the study) (3) Analgesics: acetaminophen
             (paracetamol), codeine, oxycodone, tramadol, etc. (However, in the case of narcotic
             analgesics, (4) systemic or low back pain or steroids (from 4 weeks prior to
             randomization until the end of the study) (5) Contraindications during other clinical
             trials Drug / taboo treatment (see 7.4)

          5. Pregnant or lactating women and appropriate contraceptive *

             * Use of hormonal contraceptive, intrauterine devices, spouse sterilization
             (vasectomy, tubal ligation, etc.), double blockage (use of spermicide in combination
             with vaginal septum, vaginal sponge or neck cap)

          6. Those who have received other clinical trial drugs within a longer period of 12 weeks
             or more than half of the half-life before screening

          7. Those who are unable to participate in the clinical trial according to the testee's
             judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>February 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eperisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

